Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00352677 · ClinicalTrials.gov registry record · Phase 1
Safety and Tolerability Study of INNO-406 to Treat Chronic Myeloid Leukemia or Acute Lymphocytic Leukemia
A Phase 1 study, sponsored by CytRx.
- Completed
- Registry status
- Phase 1
- Development phase
- 100
- Enrollment target
NCT00352677 is a Phase 1 study that has completed, run by CytRx. The registered enrollment target is 100 participants.
The verdict
NCT00352677, a Phase 1 study, has completed, sponsored by CytRx.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 100 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the safety and effectiveness of INNO-406 in adult patients with imatinib-resistant or intolerant Philadelphia chromosome-positive (Ph+) leukemias.
Interventions
- DRUG INNO-406
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2006-07 |
| Est. Completion | 2008-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00352677
The ClinicalTrials.gov registry entry for NCT00352677 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is CytRx, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which INNO-406 is the first listed.
NCT00352677 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00352677 about?
NCT00352677 is a clinical study titled "Safety and Tolerability Study of INNO-406 to Treat Chronic Myeloid Leukemia or Acute Lymphocytic Leukemia". The purpose of this study is to determine the safety and effectiveness of INNO-406 in adult patients with imatinib-resistant or intolerant Philadelphia chromosome-positive (Ph+) leukemias.
What is the current status of trial NCT00352677?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 100 participants. The study started on 2006-07. Estimated completion is 2008-05.
What interventions are being tested in trial NCT00352677?
The interventions under investigation include: INNO-406 (DRUG).
Who is sponsoring clinical trial NCT00352677?
This trial is sponsored by CytRx, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.